Just to lighten the mood as we all try to figure out what is going on with today's news, here is what I found on the ESC 2017 website for the August 2017 meeting.

European Society of Cardiology Congress, August 26-30, 2017, Barcelona Spain

Go to their itinerary planner and search for "apabetalone" or "resverlogix".

August 26 Satellite Symposium "Managing diabetes & cardiovascular disease (CVD): is epigenetics a new way forward?" featuring:

• "Managing high risk diabetes patient with cardiovascular disease: what works, and what else can we do?" by Kausik Ray
• "Promise of epigenetic modulation as a target in atherosclerotic patients." by Erik Stroes
• "Insights from the first trials in epigenetics in human: what is the way forward?" by Stephen Nicholls

August 27 Poster (speaker Jan JOHANSSON) "Lowering the neutrophil to lymphocyte ratio by the BET inhibitor, apabetalone: potential implications for cardiovascular events in high risk patients"

August 27 moderated poster (speaker Daisuke SHISHIKURA from Adelaide, Australia) "The effect of apabetalone on attenuated coronary atherosclerotic plaque: insights from the ASSURE trial."

August 29 poster (speaker Ewelina KULIKOWSKI) "Apabetalone (RVX-208) impacts key biomarkers and pathways associated with cardiovascular disease in patients with severe renal impairment"